• Je něco špatně v tomto záznamu ?

Identification of Plasmatic MicroRNA-206 as New Predictor of Early Recurrence of Atrial Fibrillation After Catheter Ablation Using Next-generation Sequencing

F. Šustr, T. Macháčková, M. Pešl, J. Svačinova, K. Trachtová, Z. Stárek, B. Kianička, O. Slabý, J. Novák

. 2024 ; 28 (3) : 301-310. [pub] 20240308

Jazyk angličtina Země Nový Zéland

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24014125

Grantová podpora
Institutional support project Fakultni Nemocnice u Svaté Anny v Brně
Specific research of the Masaryk University MUNI/A/1156/2021 Ministerstvo Školství, Mládeže a Tělovýchovy
"National Institute for Research of Metabolic European Union Next Generation
Cardiovascular Diseases" (Programme EXCELES European Union Next Generation
No. LX22NPO5104) European Union Next Generation

E-zdroje Online Plný text

NLK ProQuest Central od 2008-05-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2008-05-01 do Před 1 rokem

Odkazy

PubMed 38459249
DOI 10.1007/s40291-024-00698-x
Knihovny.cz E-zdroje

BACKGROUND: Catheter ablation (CA) of atrial fibrillation (AF) is indicated in patients with recurrent and symptomatic AF episodes. Despite the strict inclusion/exclusion criteria, AF recurrence after CA remains high. Identification of a novel biomarker that would predict AF recurrence would help to stratify the patients. The aim of the study was to seek novel biomarkers among the plasmatic microRNAs (miRNAs, miRs). METHODS: A prospective monocentric study was conducted. A total of 49 consecutive AF patients indicated for CA were included. Blood sampling was performed prior to CA. RNA was isolated from plasma using commercial kits. In the exploration phase, small RNA sequencing was performed in ten AF patients (five with and five without AF recurrence) using Illumina instrument. In the validation phase, levels of selected miRNAs were determined using quantitative reverse transcription polymerase chain reaction (qRT-PCR) in all participants. RESULTS: Altogether, 22 miRNAs were identified as altered between the groups by next-generation sequencing (using the DESeq2 algorithm). Using qRT-PCR, levels of the five most altered miRNAs (miR-190b/206/326/505-5p/1296-5p) were verified in the whole cohort. Plasma levels of hsa-miR-206 were significantly higher in patients with early (within 6 months) AF recurrence and showed an increase of risk recurrence,2.65 times by every increase in its level by 1 unit in the binary logistic regression. CONCLUSION: We have identified a set of 22 plasmatic miRNAs that differ between the patients with and without AF recurrence after CA and confirmed hsa-miR-206 as a novel miRNA associated with early AF recurrence. Results shall be verified in a larger independent cohort.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014125
003      
CZ-PrNML
005      
20240905134101.0
007      
ta
008      
240725s2024 nz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s40291-024-00698-x $2 doi
035    __
$a (PubMed)38459249
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Šustr, Filip $u 2nd Department of Internal Medicine, St. Anne's University Hospital in Brno and Faculty of Medicine of Masaryk University, Pekařská 53, 602 00, Brno, Czech Republic $u Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Identification of Plasmatic MicroRNA-206 as New Predictor of Early Recurrence of Atrial Fibrillation After Catheter Ablation Using Next-generation Sequencing / $c F. Šustr, T. Macháčková, M. Pešl, J. Svačinova, K. Trachtová, Z. Stárek, B. Kianička, O. Slabý, J. Novák
520    9_
$a BACKGROUND: Catheter ablation (CA) of atrial fibrillation (AF) is indicated in patients with recurrent and symptomatic AF episodes. Despite the strict inclusion/exclusion criteria, AF recurrence after CA remains high. Identification of a novel biomarker that would predict AF recurrence would help to stratify the patients. The aim of the study was to seek novel biomarkers among the plasmatic microRNAs (miRNAs, miRs). METHODS: A prospective monocentric study was conducted. A total of 49 consecutive AF patients indicated for CA were included. Blood sampling was performed prior to CA. RNA was isolated from plasma using commercial kits. In the exploration phase, small RNA sequencing was performed in ten AF patients (five with and five without AF recurrence) using Illumina instrument. In the validation phase, levels of selected miRNAs were determined using quantitative reverse transcription polymerase chain reaction (qRT-PCR) in all participants. RESULTS: Altogether, 22 miRNAs were identified as altered between the groups by next-generation sequencing (using the DESeq2 algorithm). Using qRT-PCR, levels of the five most altered miRNAs (miR-190b/206/326/505-5p/1296-5p) were verified in the whole cohort. Plasma levels of hsa-miR-206 were significantly higher in patients with early (within 6 months) AF recurrence and showed an increase of risk recurrence,2.65 times by every increase in its level by 1 unit in the binary logistic regression. CONCLUSION: We have identified a set of 22 plasmatic miRNAs that differ between the patients with and without AF recurrence after CA and confirmed hsa-miR-206 as a novel miRNA associated with early AF recurrence. Results shall be verified in a larger independent cohort.
650    _2
$a lidé $7 D006801
650    12
$a fibrilace síní $x genetika $x krev $x diagnóza $x chirurgie $7 D001281
650    12
$a mikro RNA $x krev $x genetika $7 D035683
650    12
$a katetrizační ablace $x škodlivé účinky $7 D017115
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé středního věku $7 D008875
650    12
$a recidiva $7 D012008
650    _2
$a senioři $7 D000368
650    12
$a biologické markery $x krev $7 D015415
650    _2
$a prospektivní studie $7 D011446
650    _2
$a prognóza $7 D011379
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Macháčková, Táňa $u Ondrej Slaby Joint Research Group, Central European Institute of Technology and Department of Biology of Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Pešl, Martin $u 1st Department of Internal Medicine, Cardioangiology, St. Anne's University Hospital in Brno and Faculty of Medicine of Masaryk University, Brno, Czech Republic
700    1_
$a Svačinova, Jana $u Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Trachtová, Karolína $u Ondrej Slaby Joint Research Group, Central European Institute of Technology and Department of Biology of Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Stárek, Zdeněk $u 1st Department of Internal Medicine, Cardioangiology, St. Anne's University Hospital in Brno and Faculty of Medicine of Masaryk University, Brno, Czech Republic
700    1_
$a Kianička, Bohuslav $u 2nd Department of Internal Medicine, St. Anne's University Hospital in Brno and Faculty of Medicine of Masaryk University, Pekařská 53, 602 00, Brno, Czech Republic
700    1_
$a Slabý, Ondřej $u Ondrej Slaby Joint Research Group, Central European Institute of Technology and Department of Biology of Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Novák, Jan $u 2nd Department of Internal Medicine, St. Anne's University Hospital in Brno and Faculty of Medicine of Masaryk University, Pekařská 53, 602 00, Brno, Czech Republic. jan.novak@fnusa.cz $u Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. jan.novak@fnusa.cz $1 https://orcid.org/0000000152042067
773    0_
$w MED00163193 $t Molecular diagnosis & therapy $x 1179-2000 $g Roč. 28, č. 3 (2024), s. 301-310
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38459249 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134055 $b ABA008
999    __
$a ok $b bmc $g 2143731 $s 1225991
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 28 $c 3 $d 301-310 $e 20240308 $i 1179-2000 $m Molecular diagnosis & therapy $n Mol Diagn Ther $x MED00163193
GRA    __
$a Institutional support project $p Fakultni Nemocnice u Svaté Anny v Brně
GRA    __
$a Specific research of the Masaryk University MUNI/A/1156/2021 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a "National Institute for Research of Metabolic $p European Union Next Generation
GRA    __
$a Cardiovascular Diseases" (Programme EXCELES $p European Union Next Generation
GRA    __
$a No. LX22NPO5104) $p European Union Next Generation
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace